Examination of long-term outcomes and potential synergistic effects with other renoprotective agents, particularly GLP-1 receptor agonists like semaglutide [28], could optimize ADPKD management strategies. This evidence concerns the gene GLP1R and autosomal dominant polycystic kidney disease.